Malignant Melanoma | Current Treatment: Physician Insights | US | 2020
Stage of disease, resectability of the primary tumor, and BRAF mutation status are key parameters influencing the treatment paradigm of malignant melanoma. BRAF/MEK inhibitor combination regimens, such as Roche / Genentech’s Zelboraf + Cotellic, Novartis’s Tafinlar + Mekinist, and, more recently, Pfizer / Array BioPharma’s Braftovi + Mektovi, are key options for melanoma patients harboring BRAF mutations, while the immune checkpoint inhibitors Keytruda (Merck & Co.) and Opdivo ± Yervoy (Bristol Myers Squibb) offer therapeutic options to patients regardless of mutation status. This content explores the key factors driving surveyed U.S. medical oncologists’ prescribing decisions for malignant melanoma.
QUESTIONS ANSWERED
- What are the current treatment practices in the adjuvant setting and factors influencing the use of BRAF/MEK or anti-PD-1 therapy?
- What is the uptake of immune checkpoint inhibitors and BRAF/MEK inhibitors for the treatment of BRAF-mutation-positive patients?
- How do drug-treatment rates vary across key malignant melanoma patient populations, according to stage of disease and line of therapy?
- What are the drivers and constraints that influence treatment decisions in the unresectable or metastatic setting for select targeted therapies?
PRODUCT DESCRIPTION
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
Markets covered: United States.
Primary research: Survey of approximately 100 U.S. medical oncologists in March and April 2020.
Key drugs covered: Keytruda, Opdivo ± Yervoy, Zelboraf, Cotellic, Tafinlar, Mekinist, Braftovi, Mektovi, Imlygic.
